Yarrow Bioscience, Inc.: venBio Global Strategic Fund V, L.P. amends Schedule 13G stake filing
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
venBio Global Strategic Fund V, L.P. filed an amended Schedule 13G with the SEC (accession 0000905148-26-004978) updating its beneficial ownership stake in Yarrow Bioscience, Inc. The amendment discloses the fund's revised position in the company's shares, though the filing summary did not specify the exact percentage or share count. Schedule 13G filings are required of investors holding passive stakes above 5% in a public company, so the update signals a change in venBio's holdings. Investors should watch for the full filing details to see whether the fund increased or trimmed its position.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
Yarrow Bioscience, Inc., venBio Global Strategic Fund V, L.P.